Roland Buelow
Chief Executive Officer at TeneoOne, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Lundstrom | M | 61 |
Open Monoclonal Technology, Inc.
 Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA.
SangStat Medical Corp.
| 17 years |
| Rick Murdock | M | - |
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | 17 years |
| Shelley Chu | M | 54 |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | - |
| Marianne Brüggemann | M | - |
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | 16 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-Jacques Bienaimé | M | 70 |
SangStat Medical Corp.
| 4 years |
| David Winter | M | 89 |
SangStat Medical Corp.
| 3 years |
| Philippe Pouletty | M | 65 |
SangStat Medical Corp.
| 14 years |
| Ronald Eastman | M | 71 |
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | - |
| Ronald Barrett | M | 68 |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | 7 years |
| Claude Miller | M | 73 |
SangStat Medical Corp.
| 3 years |
| Stephen Aselage | M | 73 |
SangStat Medical Corp.
| 5 years |
| Steve G. Dance | M | 72 |
SangStat Medical Corp.
| 4 years |
| Carole Nüchterlein | F | 62 |
SangStat Medical Corp.
| 3 years |
| John Orwin | M | 59 |
SangStat Medical Corp.
| 2 years |
| Jeff Ajer | M | 61 |
SangStat Medical Corp.
| - |
| Sandra Cavanah Tucher | F | - |
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 16 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Roland Buelow
- Personal Network
